Background/Purpose: Systemic-onset juvenile idiopathic arthritis (sJIA) is a pediatric autoinflammatory condition, known for significant variability between patients in its severity and long-term outcomes. The classification of disease course into monophasic, polyphasic (intermittent) and persistent disease has been commonly used, with polyphasic disease usually recognized in a small portion of patients^1,2 . However, this proportion was established according to data mostly collected before the biologic IL-1 and IL-6 inhibitors were available. It has been recently suggested ^3,4 that these medications, now the mainstay of treatment in sJIA, can potentially alter the long-term course of the disease, especially with earlier use.

Methods: : A multi-center, retrospective chart review was conducted from 3 hospitals in Israel and 2 in the US, involving patients diagnosed with sJIA between 1998-2019, with a minimum follow-up of 1 year. Disease course classification was done according to previously released definitions.¹ Drug-free remission was defined as inactive disease (no active signs or symptoms and no elevation of inflammatory markers) while not receiving any medications for a period of at least 3 months. Polyphasic disease was defined as at least one disease relapse after a period of drug-free remission. Persistent disease was defined as at least 2 years of disease (either active or in remission on immunosuppressive medication) with no drug-free remissions. Monophasic disease was defined as a single episode lasting less than 2 years.

Results: 85 patients met the inclusion criteria, with a median follow up time of 2.8 years (IQR 1.1-1.7). 54 (63.5%) of the patients were female; mean age at diagnosis was 6.3 ± 4.3 years. 67 (78.9%) were diagnosed in 2012 or later, when IL-1 and IL-6 inhibitors became widely used. 52 (61.2%) were treated with an IL-1/6 inhibitor during their disease course. The rates of monophasic, polyphasic and persistent disease were 41.2%, 44.7% and 14.1%, respectively, with a higher-than-expected rate of polyphasic disease and a lower rate of persistent disease than previously published. ^1,2,5

Conclusion: In the age of IL-1 and IL-6 inhibitors, polyphasic sJIA disease course may be more common than previously described, suggesting that cytokine blockers may potentially alter the natural history of this disease.

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/proportion-of-patients-with-a-polyphasic-disease-course-in-systemic-onset-juvenile-idiopathic-arthritis-may-be-higher-in-the-age-of-cytokine-inhibitors-2/